Sinapis Pharma Commences Phase I Trial

Company developing IV methamphetamine as a neuroprotective brain injury and stroke treatment

JACKSONVILLE, Fla., June 21 /PRNewswire/ -- Sinapis Pharma, Inc. announces that its first patients were dosed in a Phase I clinical trial study on June 14, 2010. This study, in human volunteers, is designed to evaluate the safety, pharmacokinetics, and absolute bioavailability of an intravenous infusion of methamphetamine. The first cohort, investigating shorter infusion times, went well. Future cohorts will evaluate longer infusion times and higher drug doses.

"We are excited to have launched the clinical development of this drug with the objective of defining the exact dosing schedule to take into a Phase II trial in traumatic brain injury or stroke," said Dr. Donald Picker, company CEO.  Sinapis hopes to be able to begin its important proof of principle Phase II trial before year end. 

Sinapis Pharma, Inc. (www.sinapispharma.com) is an early stage biotechnology company whose lead compound methamphetamine, as a low-dose intravenous infusion, has shown remarkable pre-clinical efficacy in stroke and brain injury models.

For more information contact Dr. Picker at [email protected].

SOURCE Sinapis Pharma, Inc.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.